These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26344096)

  • 1. Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation.
    An J; Ren S; Murphy SJ; Dalangood S; Chang C; Pang X; Cui Y; Wang L; Pan Y; Zhang X; Zhu Y; Wang C; Halling GC; Cheng L; Sukov WR; Karnes RJ; Vasmatzis G; Zhang Q; Zhang J; Cheville JC; Yan J; Sun Y; Huang H
    Mol Cell; 2015 Sep; 59(6):904-16. PubMed ID: 26344096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.
    Gan W; Dai X; Lunardi A; Li Z; Inuzuka H; Liu P; Varmeh S; Zhang J; Cheng L; Sun Y; Asara JM; Beck AH; Huang J; Pandolfi PP; Wei W
    Mol Cell; 2015 Sep; 59(6):917-30. PubMed ID: 26344095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPOP Mutations or ERG Rearrangements Result in Enhanced Levels of ERG to Promote Cell Invasion in Prostate Cancer.
    Duan S; Pagano M
    Mol Cell; 2015 Sep; 59(6):883-4. PubMed ID: 26384661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.
    Zhang P; Gao K; Tang Y; Jin X; An J; Yu H; Wang H; Zhang Y; Wang D; Huang H; Yu L; Wang C
    Hum Mutat; 2014 Sep; 35(9):1142-51. PubMed ID: 24990631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
    Shoag J; Liu D; Blattner M; Sboner A; Park K; Deonarine L; Robinson BD; Mosquera JM; Chen Y; Rubin MA; Barbieri CE
    J Clin Invest; 2018 Jan; 128(1):381-386. PubMed ID: 29202479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
    Tan Y; Ci Y; Dai X; Wu F; Guo J; Liu D; North BJ; Huo J; Zhang J
    Oncotarget; 2017 Jul; 8(29):47890-47901. PubMed ID: 28599312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
    Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
    Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
    Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
    Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.
    Wang S; Kollipara RK; Humphries CG; Ma SH; Hutchinson R; Li R; Siddiqui J; Tomlins SA; Raj GV; Kittler R
    Oncotarget; 2016 Oct; 7(40):64921-64931. PubMed ID: 27626314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
    Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
    Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
    Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J
    Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase.
    Zhu H; Ren S; Bitler BG; Aird KM; Tu Z; Skordalakes E; Zhu Y; Yan J; Sun Y; Zhang R
    Cell Rep; 2015 Nov; 13(6):1183-1193. PubMed ID: 26527005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
    An J; Wang C; Deng Y; Yu L; Huang H
    Cell Rep; 2014 Feb; 6(4):657-69. PubMed ID: 24508459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Truncated ERG proteins affect the aggressiveness of prostate cancer.
    Wu F; Ding S; Lu J
    Med Hypotheses; 2013 Apr; 80(4):490-3. PubMed ID: 23357671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
    Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
    Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions.
    Jiang Q; Zheng N; Bu L; Zhang X; Zhang X; Wu Y; Su Y; Wang L; Zhang X; Ren S; Dai X; Wu D; Xie W; Wei W; Zhu Y; Guo J
    Mol Cancer; 2021 Aug; 20(1):100. PubMed ID: 34353330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
    Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
    Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3β and WEE1.
    Hong Z; Zhang W; Ding D; Huang Z; Yan Y; Cao W; Pan Y; Hou X; Weroha SJ; Karnes RJ; Wang D; Wu Q; Wu D; Huang H
    Mol Cell; 2020 Sep; 79(6):1008-1023.e4. PubMed ID: 32871104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
    Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
    Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
    Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C
    Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.